Case Report

A Rare Laryngeal Tumor: Poorly Differentiated Primary Small Cell Neuroendocrine Carcinoma

Volume 19 · Issue 3 Publish Date: July 15, 2023
Full Text PDF
DOI
Arie Frank Arensman
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Laura Pingnet
Department of ENT (Ear Nose Throat), GZA-ziekenhuizen, Campus Sint-Vincentius, Antwerp, Belgium
Martin Lammens
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Simon Nicolay
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Olivier M. Vanderveken
Department of Otorhinolaryngology, Head and Neck Surgery, Antwerp University Hospital, Edegem, Antwerp, Belgium
Arensman, A. F., Pingnet, L., Lammens, M., Nicolay, S., & Vanderveken, O. M. (2023). A Rare Laryngeal Tumor: Poorly Differentiated Primary Small Cell Neuroendocrine Carcinoma. B-ENT, 19(3), 188–191. https://doi.org/10.5152/B-ENT.2023.21524
Full Text Full Text PDF

Abstract

Laryngeal small-cell neuroendocrine carcinoma is a rare and aggressive type of tumor. Due to the poor degree of differentiation, laryngeal small cell neuroendocrine carcinoma has particularly aggressive biological behavior with a tendency to early and widespread dissemination resulting in a poor prognosis. Based on presenting symptoms and imaging appearance, no differentiation is possible between laryngeal small cell neuroendocrine carcinoma and other laryngeal malignancies. Laryngeal small-cell neuroendocrine carcinoma is distinguished from other types of malignancies with histological examination complemented by immunohistochemistry. Due to its rareness, an evidence-based approach is lacking. The treatment principles are deducted from treatment protocols of small cell lung cancer and individual clinician’s experience. The suggested preferred treatment of laryngeal small cell neuroendocrine carcinoma is a combination of chemotherapeutic agents. The prognosis is poor with a reported 5-year disease-specific survival of 18%-30%. Systemic dissemination at initial presentation is the only variable associated with a worse prognosis and treatment modality does not affect prognosis. Cite this article as: Arensman AF, Pingnet L, Lammens M, Nicolay S, Vanderveken OM. A rare laryngeal tumor: Poorly differentiated primary small cell neuroendocrine carcinoma. B-ENT. 2023;19(3):188-191.

Similar Articles

Article Info
Published In
Journal B-ENT
Volume / Issue Volume 19 · Issue 3
Pages 188-191
History
Published Online July 15, 2023
Affiliations
Arie Frank Arensman
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Laura Pingnet
Department of ENT (Ear Nose Throat), GZA-ziekenhuizen, Campus Sint-Vincentius, Antwerp, Belgium
Martin Lammens
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Simon Nicolay
University of Antwerp Faculty of Medicine and Health Sciences, Antwerp, Belgium
Olivier M. Vanderveken
Department of Otorhinolaryngology, Head and Neck Surgery, Antwerp University Hospital, Edegem, Antwerp, Belgium
Cite this Article
Arensman, A. F., Pingnet, L., Lammens, M., Nicolay, S., & Vanderveken, O. M. (2023). A Rare Laryngeal Tumor: Poorly Differentiated Primary Small Cell Neuroendocrine Carcinoma. B-ENT, 19(3), 188–191. https://doi.org/10.5152/B-ENT.2023.21524
Outlines